Trial Profile
Phase II Trial Of Karenitecin (IND 57250) In Patients With Relapsed or Refractory Non-small Cell Lung Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Cositecan (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 18 Sep 2005 New trial record.